Guidelines advocate primary preventive ICDs for patients with LVEF ≤35% after >40 days after AMI, but a delay of at least 3 months is recommended after revascularization. Implantation of primary preventive ICDs is also recommended for patients with LVEF ≤40%, nonsustained ventricular arrhythmias (ventricular tachyarrhythmias) caused by prior AMI, and inducible ventricular tachyarrhythmias during electrophysiological studies. 13 The optimal timing for ICD implantation has not been evaluated in prospective studies.14 A substudy of Multicenter Automatic Defibrillator Implantation Trial (MADIT) II showed more benefit with ICD in patients with more remote AMI, 15 but post hoc analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) study implicates that the duration after AMI does not modify Background-Implantable cardioverter-defibrillator therapy improves survival in patients with reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI). Although the risk of sudden cardiac death is highest in the first month after AMI, there is no survival benefit of early implantable cardioverter-defibrillator implantation, and the optimal time frame has yet to be established. Thus, the aim of this study was to investigate what proportion of post-AMI patients had improved LV function to such an extent that the indication for implantable cardioverter-defibrillator was no longer present. Methods and Results-Patients admitted for AMI with reduced LVEF (≤40%) were eligible for inclusion. Repeat echocardiographic examinations were performed 5 days, 1 month, and 3 months after the AMI. We prospectively included 100 patients with LVEF of 31±5.8% after AMI. At the 1-month follow-up, 55% had an LVEF >35%. The main improvement in LVEF had occurred by 1 month. The mean difference in LVEF over the next 2 months was small, 1.9 percentage units. During the first 9 weeks, 10% of the patients suffered from life-threatening arrhythmias. Conclusions-Most patients have improved LVEF after AMI, and in the majority, the improvement can be confirmed after 1 month, implying that further delay of implantable cardioverter-defibrillator implantation may not be warranted. The aim of this study was to investigate what proportion of patients with reduced LV function after an AMI reached an LVEF >35%, thereby no longer qualifying for ICD treatment. We also investigated the time to improvement to allow earlier identification of possible ICD candidates. MethodsPatients admitted with AMI at Danderyd University Hospital or Södersjukhuset in Stockholm between November 2010 and December 2013 were eligible for participation in the study if a clinical echocardiography showed an LVEF of ≤40%. An AMI was defined according to the second and third universal definitions of myocardial infarction. 19,20 All clinical echocardiographies of potentially eligible patients were reviewed by a participating research cardiologist with echocardiographic expertise who confirmed that the LVEF was indeed ≤40% according to the modified Simpso...
The rate of false-positive catheterization laboratory activations based on pre-hospital ECGs was low and the target of PCI within 60 minutes is achievable for a majority of patients. Efforts should be made to reduce the time from ambulance arrival to PH-ECG transmission, especially for female patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.